• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

晚期激素敏感性前列腺癌患者的生活以及阿比特龙和雄激素剥夺治疗:患者、护理人员及医生的视角

Living with Advanced Hormone-Sensitive Prostate Cancer and Treatment with Abiraterone and Androgen Deprivation Therapy: The Patient, Nursing and Physician Perspective.

作者信息

Collier Tony, Smith Shievon, Greenwood Michelle, Ng Kenrick

机构信息

Prostate Cancer UK, 53 Tooley Street, London, SE1 2QN, UK.

St Bartholomew's Hospital, Barts Health NHS Trust, London, EC1A 7BE, UK.

出版信息

Oncol Ther. 2020 Dec;8(2):197-207. doi: 10.1007/s40487-020-00132-2. Epub 2020 Oct 9.

DOI:10.1007/s40487-020-00132-2
PMID:33037517
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7546153/
Abstract

This article is co-authored by a patient with metastatic hormone-sensitive prostate cancer who is receiving abiraterone and androgen deprivation therapy treatment in Manchester, UK. The patient relates his personal experiences struggling with the diagnosis, his experience with treatment and the physical, emotional and psychosexual impact on his life. After his diagnosis, the patient has become an outspoken advocate and fundraiser for prostate cancer awareness and wants to ensure that novel treatments with proven efficacy and tolerability, such as abiraterone, are available for all men in his condition. The specialist nursing and physician perspectives, provided by healthcare professionals based in London who are not directly involved in this patient's care, were written in response to the challenges and concerns highlighted by this patient. The role of the specialist nurse as a key healthcare professional in the cancer patient journey, particularly in managing the complex physical and emotional side effects of treatment, is highlighted in this perspective piece. The physician reviews the current difficulties of establishing an effective screening programme in prostate cancer, the common side effects of hormone treatment and the significant progress and challenges in novel drug development and prescription in metastatic hormone-sensitive prostate cancer. While written primarily from the perspective of a patient and healthcare professionals in England, many messages in this commentary would resonate with patients and professionals involved in the care of prostate cancer worldwide.

摘要

本文由一名转移性激素敏感性前列腺癌患者共同撰写,该患者正在英国曼彻斯特接受阿比特龙和雄激素剥夺治疗。患者讲述了自己在面对诊断时的挣扎经历、治疗体验以及治疗对其生活在身体、情感和性心理方面的影响。确诊后,该患者成为了前列腺癌认知的直言倡导者和筹款人,并希望确保像阿比特龙这样已证实具有疗效和耐受性的新型治疗方法能供所有处于他这种情况的男性使用。由伦敦的医疗保健专业人员提供的专科护理和医生观点,他们未直接参与该患者的护理,是针对该患者所强调的挑战和担忧而撰写的。在这篇观点文章中,突出了专科护士作为癌症患者治疗过程中关键医疗保健专业人员的作用,尤其是在管理治疗复杂的身体和情感副作用方面。医生回顾了当前在前列腺癌中建立有效筛查项目的困难、激素治疗的常见副作用以及转移性激素敏感性前列腺癌新药研发和处方方面的重大进展和挑战。虽然本文主要是从一名英国患者和医疗保健专业人员的角度撰写的,但这篇评论中的许多信息会引起全球参与前列腺癌护理的患者和专业人员的共鸣。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4279/7683635/9935a1938a98/40487_2020_132_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4279/7683635/23416ba6f4e6/40487_2020_132_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4279/7683635/9935a1938a98/40487_2020_132_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4279/7683635/23416ba6f4e6/40487_2020_132_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4279/7683635/9935a1938a98/40487_2020_132_Fig2_HTML.jpg

相似文献

1
Living with Advanced Hormone-Sensitive Prostate Cancer and Treatment with Abiraterone and Androgen Deprivation Therapy: The Patient, Nursing and Physician Perspective.晚期激素敏感性前列腺癌患者的生活以及阿比特龙和雄激素剥夺治疗:患者、护理人员及医生的视角
Oncol Ther. 2020 Dec;8(2):197-207. doi: 10.1007/s40487-020-00132-2. Epub 2020 Oct 9.
2
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.EAU 前列腺癌指南。第二部分:晚期、复发性和去势抵抗性前列腺癌的治疗。
Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12.
3
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.阿比特龙联合泼尼松加至去势治疗和多西他赛用于初治转移性去势敏感性前列腺癌(PEACE-1):一项采用2×2析因设计的多中心、开放标签、随机3期研究。
Lancet. 2022 Apr 30;399(10336):1695-1707. doi: 10.1016/S0140-6736(22)00367-1. Epub 2022 Apr 8.
4
Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.靶向转移性激素敏感型前列腺癌:化疗联合激素治疗及新的联合治疗策略
J Urol. 2019 May;201(5):876-885. doi: 10.1097/JU.0000000000000117.
5
Veterans Affairs Prostate Cancer Treatment Sequencing (VAPCaTS): A Real-World Evidence Study of Men with Metastatic Prostate Cancer.退伍军人事务部前列腺癌治疗序列(VAPCaTS):一项针对转移性前列腺癌男性患者的真实世界证据研究。
Urol Pract. 2021 Jan;8(1):112-118. doi: 10.1097/UPJ.0000000000000166. Epub 2020 May 29.
6
A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer.转移性激素敏感型前列腺癌系统治疗的成本效益分析
Eur Urol Oncol. 2019 Nov;2(6):649-655. doi: 10.1016/j.euo.2019.01.004. Epub 2019 Jan 30.
7
Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.转移性激素敏感性前列腺癌一线药物治疗的现状及初始治疗的未来展望
Int J Urol. 2016 May;23(5):360-9. doi: 10.1111/iju.13091. Epub 2016 Apr 8.
8
Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy.醋酸阿比特龙/雄激素剥夺疗法联合方案与多西他赛/雄激素剥夺疗法联合方案治疗晚期激素敏感性前列腺癌的疗效与安全性的网状Meta分析
Curr Med Res Opin. 2018 May;34(5):903-910. doi: 10.1080/03007995.2018.1447450. Epub 2018 Mar 27.
9
Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy.醋酸阿比特龙联合泼尼松治疗前列腺癌的安全性和有效性。
Expert Rev Anticancer Ther. 2020 Aug;20(8):629-638. doi: 10.1080/14737140.2020.1785289. Epub 2020 Jun 25.
10
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.醋酸阿比特龙联合泼尼松或联合恩扎卢胺治疗开始去势治疗的转移性前列腺癌患者:STAMPEDE 平台方案两项随机 3 期试验的最终结果。
Lancet Oncol. 2023 May;24(5):443-456. doi: 10.1016/S1470-2045(23)00148-1.

引用本文的文献

1
Patient engagement in designing and publishing research in prostate cancer: a scoping review.患者参与前列腺癌研究的设计和发表:范围综述。
Future Oncol. 2024;20(35):2779-2790. doi: 10.2217/fon-2023-0543. Epub 2024 Apr 4.

本文引用的文献

1
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting.转移性激素敏感性前列腺癌(mHSPC):一线治疗中的进展与治疗策略
Oncol Ther. 2020 Dec;8(2):209-230. doi: 10.1007/s40487-020-00119-z. Epub 2020 Jun 15.
2
Prostate cancer in young men: An emerging young adult and older adolescent challenge.青年男性前列腺癌:新兴的青年成年和大龄青少年挑战。
Cancer. 2020 Jan 1;126(1):46-57. doi: 10.1002/cncr.32498. Epub 2019 Sep 25.
3
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
阿帕鲁胺治疗转移性去势敏感性前列腺癌。
N Engl J Med. 2019 Jul 4;381(1):13-24. doi: 10.1056/NEJMoa1903307. Epub 2019 May 31.
4
Exercise interventions and their effect on masculinity, body image, and personal identity in prostate cancer-A systematic qualitative review.锻炼干预及其对前列腺癌患者男性气质、身体意象和个人认同的影响:系统定性评价。
Psychooncology. 2019 Jun;28(6):1184-1196. doi: 10.1002/pon.5060. Epub 2019 Apr 24.
5
Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss.随机 II 期研究评估 Akt 阻断联合阿比特龙治疗伴有或不伴有 PTEN 缺失的转移性前列腺癌患者的疗效。
Clin Cancer Res. 2019 Feb 1;25(3):928-936. doi: 10.1158/1078-0432.CCR-18-0981. Epub 2018 Jul 23.
6
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.新诊断转移性去势敏感性前列腺癌患者中阿比特龙联合泼尼松添加到雄激素剥夺治疗后的患者报告结局(LATITUDE):一项国际性、随机 3 期临床试验。
Lancet Oncol. 2018 Feb;19(2):194-206. doi: 10.1016/S1470-2045(17)30911-7. Epub 2018 Jan 8.
7
A Meta-Synthesis of Qualitative Studies Exploring Men's Sense of Masculinity Post-Prostate Cancer Treatment.一项探索男性前列腺癌治疗后男子气概观念的定性研究的元分析。
Cancer Nurs. 2018 Jul/Aug;41(4):298-310. doi: 10.1097/NCC.0000000000000509.
8
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.多参数 MRI 和 TRUS 活检在前列腺癌(PROMIS)中的诊断准确性:一项配对验证性研究。
Lancet. 2017 Feb 25;389(10071):815-822. doi: 10.1016/S0140-6736(16)32401-1. Epub 2017 Jan 20.
9
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.局限性前列腺癌监测、手术或放疗 10 年后的结果。
N Engl J Med. 2016 Oct 13;375(15):1415-1424. doi: 10.1056/NEJMoa1606220. Epub 2016 Sep 14.
10
Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.50-69 岁男性前列腺癌筛查(STHLM3):一项前瞻性基于人群的诊断研究。
Lancet Oncol. 2015 Dec;16(16):1667-76. doi: 10.1016/S1470-2045(15)00361-7. Epub 2015 Nov 10.